NFKB1 and diabetes mellitus: They can be used for the treatment of diabetes through the regulation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathway [158, 161].